Kim_2025_J.Ginseng.Res_49_342

Recently, the development of the FDA approved monoclonal antibodies (mAbs) targeting amyloid proteins, such as aducanumab, lecanemab, and donanemab, etc. Although these are in initial stage, developing mAbs is believed to proposed as next stage of AD therapeutics. However, their high cost makes them impractical as main stream of dementia treatments, and efficacies might not overcome the current AchEI (Acetyl choline Esterase Inhibitors). AchEI compliance issues are caused by side effects, such as nausea or vomiting due to Ach's adverse event. There are several categories of medicines, nootropics, functional foods that enhance cognition. These usually have used together or sometimes independently. In addition to conventional anti-AD medication, however, efficacy re-evaluation in Korea to assess which may for the physicians to prohibit further prescription. These situations, too-high-cost of advanced new drugs, compliance issues of current medications and re-evaluation of nootropics are facing the ultra-expanding dementia population in South Korea. Korean Red Ginseng has been recognized for cognitive enhancement properties. Additionally, pleiotropic phenomena of KRG, not only cognition but also overall human health systems, warranting further underling medical evidence. These efficacies and multi-effectiveness can be a high potential candidate for the current trends in developing strategies for dementia disorders.